Comparison · NCT00729586-51a42cfa
Arm 1: Temsirolimus vs Arm 2: Megestrol Acetate+Tamoxifen+ Temsirolimus: Incidence of Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events Version 3.0
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm 1: Temsirolimus vs Arm 2: Megestrol Acetate+Tamoxifen+ Temsirolimus: Incidence of Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events Version 3.0. Trial comparisons, record NCT00729586-51a42cfa. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00729586-51a42cfa
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.58 | 0.442 | 0.706 | wilson | |
| Risk in group 2 | 0.714 | 0.5 | 0.862 | wilson | |
| Risk difference, group 1 minus group 2 | -0.134 | -0.336 | 0.114 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.812 | 0.567 | 1.16 | log | |
| Odds ratio, group 1 over group 2 | 0.552 | 0.184 | 1.66 | log | |
| Number needed to treat, for one fewer participant with the outcome on Arm 1: Temsirolimus than on Arm 2: Megestrol Acetate+Tamoxifen+ Temsirolimus | 7.45 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm 1: Temsirolimus | Temsirolimus IV 25 mg (flat dose) weekly | 29 | 50 | OG000 |
| Group 2 | Arm 2: Megestrol Acetate+Tamoxifen+ Temsirolimus | Megestrol Acetate (MA) 80 mg bid for three weeks alternating with Tamoxifen (T) 20 mg bid for 3 weeks PLUS Temsirolimus IV 25 mg (flat dose) weekly | 15 | 21 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Incidence of Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events Version 3.0
- Description
- Number of participants with a maximum grade of 3 or higher during the treatment period.
- Time frame
- Assessed every 6 weeks while on treatment, 30 days after the last cycle of treatment.
- Population
- Eligible and treated patients
Source ClinicalTrials.gov
Trial
- Title
- Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
- NCT number
- NCT00729586
- Phases
- PHASE2
- Conditions
Endometrial Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC1 Uterine Corpus Cancer, Stage IIIC2 Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
- Interventions
- Laboratory Biomarker Analysis, Megestrol Acetate, Tamoxifen Citrate, Temsirolimus
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2018-08-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00729586?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00729586-51a42cfa